Therapeutic Revolution Promises Vision Restoration for Keratopathy Patients
Researchers at Moorfields Eye Hospital and University College London have announced a revolutionary, unprecedented breakthrough in the treatment of vision loss caused by aniridia-associated keratopathy, a rare and chronic disease that leads to gradual vision loss. The scientific team explained that they developed a new technique known as “RAFT-OS,” which relies on a collagenous scaffold seeded with two different types of stem cells derived from donors.
The study, whose results were published in JAMA Ophthalmology, confirmed that this new technique addresses the root of the problem by replacing the limbal epithelial cell layer responsible for regenerating the corneal surface, along with keratinocyte stem cells that provide structural support for deep tissues. The first clinical trial on humans included nine adults suffering from advanced stages of the disease.
The results showed significant improvement, with the mean ocular surface score decreasing from 9.4 to 5.9 after three months in treated eyes, while untreated eyes showed no significant change. Furthermore, treated eyes gained an average of 24 letters on the standard visual acuity chart, equivalent to approximately five lines of visual improvement.
Among the key findings and details of this clinical trial are the following:
• The ocular surface score decreased significantly in treated eyes over three months, reflecting improved corneal health.
• Patients achieved an average improvement of 24 letters in visual acuity tests, a strong indicator of restored visual function.
• Some side effects were recorded, including one serious adverse event that led to protocol modification, and two cases of persistent epithelial defects.
These results represent a highly promising outlook for a condition previously considered untreatable. Although the small sample size in this initial phase calls for broader studies to confirm long-term efficacy, this innovative approach opens new horizons for treating millions of patients worldwide suffering from this rare disease.
